Annie Luetkemeyer, MD, professor of infectious diseases at UCSF, is an expert on the treatment of viral infections. Robert Wachter, MD, MHM, chair of the UCSF Department of Medicine, interviewed her about the evidence behind potential treatments for COVID-19 (including chloroquine/hydroxychloroquine, remdesivir, and others), as well as how to assess new and existing drugs in a pandemic.
Clinical
Treatment options for COVID-19: Dr. Annie Luetkemeyer
Next Article:
Comments ()
Clinical
-
COVID-19 linked to multiple cardiovascular presentations -
-
Nearly 24 tests for the novel coronavirus are available -
-
U.S. hospitals facing severe challenges from COVID-19, HHS report says -
-
-
-
-
Neurologic symptoms and COVID-19: What’s known, what isn’t
Quality
Public Policy
Practice Management
-
-
-
Maintaining cancer care in the face of COVID-19 -
Firings, furloughs, and pay cuts in advance of COVID-19 surge -
-
U.S. lifts visa halt to boost COVID-19 physician workforce -
-
Guidelines on delaying cancer surgery during COVID-19 -
-
New ASAM guideline released amid COVID-19 concerns
From the Society
Video
-
Critical care and COVID-19: Dr. Matt Aldrich -
Treatment options for COVID-19: Dr. Annie Luetkemeyer -
Managing the COVID-19 isolation floor at UCSF Medical Center -
-
